Literature DB >> 27726099

Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I-IIIA non-small cell lung cancer.

Xuan Hong1, Zhaoyang Yang1, Meng Wang1, Li Wang2, Qingyong Xu3.   

Abstract

Decorin, chiefly synthesized by tumor stroma, is known as a tumor suppressor. However, the clinical and prognostic significance in lung cancer remained unclear. Here, decorin and Ki67 expression was detected by immunohistochemistry (IHC) in I-IIIA non-small cell lung cancer (NSCLC) tissues (n = 264) in comparison to adjacent normal tissues (n = 40). The relationship between the expression of decorin and clinical characteristics, as well as Ki67 index and prognosis, was analyzed. Decorin expression was decreased in both the stroma (P < 0.001) and the tumor cells (P = 0.038) in NSCLC specimens. There was the lowest stromal expression of decorin in patients with G3 adenocarcinoma and higher Ki67 index in the stromal decorin-negative group. The Kaplan-Meier survival analysis demonstrated that lack of decorin in the stroma was correlated with a shorter DFS and OS (P = 0.005 and P = 0.010, respectively), while there was no significant association between decorin expression in the tumor cells and outcome. Multivariate analysis showed that reduced expression of decorin in the stroma was an independent prognostic factor for poor outcome including DFS (HR = 5.685, 95 % CI 0.493-0.933; P = 0.017) and OS (HR = 6.579, 95 % CI 0.484-0.908; P = 0.010). Negative decorin in the stroma combined with high Ki67 index predicted poorer outcomes for I-IIIA NSCLC patients. Our results provide data on decorin expression in both the stroma and cancer cells in NSCLC and reveal that reduced expression of stromal decorin correlates with high Ki67 index and has prognostic significance for poor outcome in I-IIIA NSCLC. Our data suggest that evaluating stromal decorin expression might be useful in assessing the prognosis and malignant potential.

Entities:  

Keywords:  Decorin; Immunohistochemistry; Ki67; Non-small cell lung cancer; Prognosis

Year:  2016        PMID: 27726099     DOI: 10.1007/s13277-016-5431-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels.

Authors:  Simone Buraschi; Nutan Pal; Nadia Tyler-Rubinstein; Rick T Owens; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

2.  Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.

Authors:  Mieke Van Bockstal; Kathleen Lambein; Olivier Gevaert; Olivier De Wever; Marleen Praet; Veronique Cocquyt; Rudy Van den Broecke; Geert Braems; Hannelore Denys; Louis Libbrecht
Journal:  Histopathology       Date:  2013-07-26       Impact factor: 5.087

Review 3.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 4.  Decorin: a guardian from the matrix.

Authors:  Thomas Neill; Liliana Schaefer; Renato V Iozzo
Journal:  Am J Pathol       Date:  2012-06-23       Impact factor: 4.307

5.  Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice.

Authors:  Xiuli Bi; Nicole M Pohl; Zhibin Qian; George R Yang; Yuan Gou; Grace Guzman; Andre Kajdacsy-Balla; Renato V Iozzo; Wancai Yang
Journal:  Carcinogenesis       Date:  2011-12-08       Impact factor: 4.944

6.  Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis.

Authors:  Xuefei Shi; Wenjun Liang; Wen Yang; Rui Xia; Yong Song
Journal:  Tumour Biol       Date:  2014-12-20

7.  Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas.

Authors:  Amy L McDoniels-Silvers; Caramella F Nimri; Gary D Stoner; Ronald A Lubet; Ming You
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

Review 8.  Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs.

Authors:  Silvia Goldoni; Renato V Iozzo
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

9.  Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation.

Authors:  Xiuli Bi; Chang Tong; Ashley Dockendorff; Laura Bancroft; Lindsay Gallagher; Grace Guzman; Renato V Iozzo; Leonard H Augenlicht; Wancai Yang
Journal:  Carcinogenesis       Date:  2008-06-12       Impact factor: 4.944

10.  Decreased decorin expression in the tumor microenvironment.

Authors:  Benedek Bozoky; Andrii Savchenko; Hayrettin Guven; Fredrik Ponten; George Klein; Laszlo Szekely
Journal:  Cancer Med       Date:  2014-03-17       Impact factor: 4.452

View more
  5 in total

1.  While Urine and Plasma Decorin Remain Unchanged in Prostate Cancer, Prostatic Tissue Decorin Has a Prognostic Value.

Authors:  Razie Rezaie; Zeinab Falakian; Saeideh Mazloomzadeh; Mohsen Ayati; Arman Morakabati; Mohammad Reza Teimouri Dastjerdan; Mohammad Zare; Minoosh Moghimi; Tina Shahani; Alireza Biglari
Journal:  Iran Biomed J       Date:  2020-04-19

2.  Study on the expression profile and role of decorin in the progression of pancreatic cancer.

Authors:  Litao Zhang; Chao Liu; Huijie Gao; Caiju Zhou; Wei Qin; Jian Wang; Lingxin Meng; Huiyun Wang; Qiang Ren; Yuntao Zhang
Journal:  Aging (Albany NY)       Date:  2021-05-21       Impact factor: 5.682

3.  Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer.

Authors:  Xiaoding Hu; Emilly S Villodre; Richard Larson; Omar M Rahal; Xiaoping Wang; Yun Gong; Juhee Song; Savitri Krishnamurthy; Naoto T Ueno; Debu Tripathy; Wendy A Woodward; Bisrat G Debeb
Journal:  Commun Biol       Date:  2021-01-15

4.  Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer.

Authors:  Tokuko Hosoya; Goshi Oda; Tsuyoshi Nakagawa; Iichiroh Onishi; Tadashi Hosoya; Megumi Ishiguro; Toshiaki Ishikawa; Hiroyuki Uetake
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

5.  Analysis of the relationship between Ki-67 expression and chemotherapy and prognosis in advanced non-small cell lung cancer.

Authors:  Diming Wang; Dongmei Chen; Chi Zhang; Mei Chai; Maojing Guan; Zhongyu Wang; Ye Wei; Yiwen Zhang; Qingming Shi; Kangsheng Gu
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.